KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Shares Outstanding (Diluted Average) (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Shares Outstanding (Diluted Average) data on record, last reported at $258.0 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) changed 0.04% year-over-year to $258.0 million; the TTM value through Dec 2025 reached $258.0 million, changed 0.04%, while the annual FY2025 figure was $258.0 million, 0.04% changed from the prior year.
  • Shares Outstanding (Diluted Average) reached $258.0 million in Q4 2025 per VRTX's latest filing, roughly flat from $257.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $261.9 million in Q1 2021 and bottomed at $257.6 million in Q3 2025.
  • Average Shares Outstanding (Diluted Average) over 5 years is $259.4 million, with a median of $259.5 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Diluted Average): fell 1.66% in 2021, then increased 0.93% in 2023.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $259.9 million in 2021, then fell by 0.31% to $259.1 million in 2022, then increased by 0.54% to $260.5 million in 2023, then fell by 1.0% to $257.9 million in 2024, then grew by 0.04% to $258.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $258.0 million in Q4 2025, $257.6 million in Q3 2025, and $258.9 million in Q2 2025.